Home/Pipeline/ENDO-995

ENDO-995

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

EndoCyclic Therapeutics

About EndoCyclic Therapeutics

EndoCyclic Therapeutics is pioneering a novel class of precision peptide therapeutics and diagnostics based on a platform technology that enables selective uptake and pH-sensitive activation within diseased cells. The company's pipeline is focused on high-need areas, including endometriosis, where it is advancing both a potential disease-modifying therapeutic (ENDO-205) and a non-invasive diagnostic (FemLUNA), as well as oncology programs. With an IND cleared for its lead candidate, EndoCyclic is positioned to address significant unmet medical needs with a targeted, non-hormonal approach that aims to avoid systemic toxicity.

View full company profile

Therapeutic Areas

Women's Health Oncology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed